ProAmpac's ProActive Recyclable® Fiber Based Technology Wins Top Honors at 2025 PAC Global Awards
CINCINNATI, February 21, 2025--(BUSINESS WIRE)--ProAmpac, a leader in flexible packaging and material science, is proud to announce that its ProActive Recyclable® RP-1000 Paper Platform, used in the Marks & Spencer's Select Farms Organic potato range, has won Best in Class and an Award of Distinction at the 2025 PAC Global Awards. The awards were presented at the PAC Global Awards Celebration and Futures Edge Summit in New York.
As part of the ProAmpac's Fiberization of Packaging® initiative, the RP-1000 platform stood out in the Sustainable Package Design: Package Circularity category for its combination of high-speed form-fill-seal performance, enhanced durability, and full curbside recyclability. This recognition reinforces ProAmpac's commitment to delivering high-performance, sustainable packaging solutions that meet evolving market and circularity demands.
"The RP-1000 series represents a major step forward in sustainable flexible packaging, balancing functionality, durability, and recyclability without compromising performance," said Abigail Sawyer-Parker, product development technologist at ProAmpac. "We really appreciate the collaboration with Marks & Spencer's and are honored that PAC Global has recognized our efforts in driving packaging circularity forward."
The PAC Global Awards celebrate innovative, impactful, and sustainable packaging solutions worldwide. Winning Best in Class and an Award of Distinction further cements ProAmpac's position as a leader in advancing circular packaging design.
For more information, please contact Marketing@ProAmpac.com or visit ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac's approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221386393/en/
Contacts
Media Contact:Whitney MilesProAmpac(617) 721 7040Whitney.Miles@ProAmpac.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
GELITA Showcases Advanced Excipient Solutions at BIO International- June 2025 in Boston
EBERBACH, Germany, June 9, 2025 /PRNewswire/ -- GELITA, a global leader in pharmaceutical gelatin and collagen peptide solutions, is proud to announce its participation as an exhibitor at BIO International 2025 in Boston. This year's presentation highlights the company's innovative excipients, MEDELLAPRO® and VACCIPRO®, meeting the specific needs of advanced pharmaceutical formulations and medical devices. GELITA's Endotoxin Controlled Excipients (ECE) portfolio, including MEDELLAPRO® (gelatin) and VACCIPRO® (collagen peptides), addresses the demanding requirements of pharmaceutical and medical applications such as vaccine stabilizers, tissue engineering, 3D bioprinting, implants and advanced wound care. In pharmaceutical, medical device and healthcare environments, endotoxin control is crucial to ensure product safety and patient well-being. MEDELLAPRO® stands out for its versatility and inherent biocompatibility, making it ideal for applications such as surgical sealants, hemostatic agents, scaffolds, 3D bioprinting and drug delivery systems. Vaccines stabilized with VACCIPRO® show very low allergenic potential, high bioavailability and excellent cell tissue affinity. VACCIPRO® is globally recognized as THE gold standard by vaccine manufacturers. With a strong commitment to quality and innovation, GELITA continues to empower the pharmaceutical and medical device industries with solutions that drive efficiency and safety in the development of life-saving therapies. GELITA is well advanced in developing biotechnological processes to produce animal-free alternatives with optimized properties that are even more resource-efficient and sustainable than conventional methods. With the pharmaceutical know-how of the GELITA Pharma Institute and GELITA's Biotech R&D Hub, the company is well-equipped to expand its biotechnological expertise and product portfolio Visit GELITA at Booth 2865-01in the German Pavilion to explore how MEDELLAPRO® and VACCIPRO® are shaping the future of vaccine development and medical devices. About GELITA GELITA is one of the leading companies for manufacturing and marketing collagen proteins. Coordinated from headquarters in Eberbach, Germany, GELITA provides customers around the world with products of the highest standard, comprehensive technical expertise and sophisticated solutions. More than 20 sites and a global expert network ensure that state-of-the-art know-how is always available for customers. GELITA's performance is based on 150 years of experience in the field of collagen proteins, and a strong desire for innovation is the driving force of the family-owned company, which is always looking for new solutions for food, pharmaceutical, health & nutrition markets, as well as for technical applications. Within its range of collagen proteins, GELITA supplies collagen peptides with proven body-stimulating capabilities as well as tailor-made gelatins. This holistic range of products in combination with its vast experience in developing solutions for different applications makes GELITA first choice for customers in every continent. In today's landscape of high consumer demands, manufacturers of food products must rely on natural, healthy, non-allergenic ingredients for successful developments. Collagen proteins from GELITA are the perfect match for this as they fulfill all these requirements, a particular plus being the fact that they are foodstuffs (i.e. no E-number). Media Contact: Amy Maggio 396407@ 312-617-6248 Company Contact: Martin Junginger (Senior Expert Global Category Management Pharma & Bioscience)GELITA AG +49 6271 84 2103 396407@ View original content to download multimedia: SOURCE GELITA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025 Resolution of partial clinical hold unlocks second tranche of funds from $12.5 million PIPE financing announced on June 3, 2025 TAMPA, Fla., June 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the FDA has removed the manufacturing-related partial clinical hold on the Company's Phase 3 accelerated approval trial for IFx-2.0, thereby allowing the trial to proceed as agreed to under the previously announced SPA Agreement with the FDA. "We are grateful for the collaborative interaction with the reviewers at the Office of Therapeutic Products (OTP) and the Oncology Center of Excellence (OCE), including their quick response time and, importantly, their helpful recommendations going forward," stated James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences. "The removal of the partial clinical hold allows TuHURA to begin the trial's initiation and activation of clinical sites for the Phase 3 accelerated approval trial of IFx-2.0," continued Dr. Bianco. "We are also pleased that the removal of the partial clinical hold represents the achievement of the second milestone funding condition under our recently announced private placement, thereunder trigging the payment to the Company of an additional $2.23 million under the financing." The Company's Phase 3 accelerated approval trial of IFx-2.0, will be conducted under an SPA Agreement with the U.S. FDA, and will evaluate IFx-2.0 as an adjunctive therapy administered weekly for three weeks concurrent with the approved dose and schedule for Keytruda® compared to Keytruda® plus placebo in the first line treatment of patients with advanced or metastatic MCC. Keytruda® is currently approved in MCC under accelerated approval based on Overall Response Rate (ORR). The pivotal trial for IFx-2.0 is expected to enroll 118 across approximately 22 to 25 U.S. sites. Trial participants will be randomized on a 1:1 basis and receive Keytruda® in both arms, for up to two years, or until disease progression or Keytruda® related toxicities. The primary endpoint for the trial is ORR with a key secondary endpoint of Progression Free Survival (PFS). Other secondary endpoints are safety, duration of response, and overall survival. Accelerated approval is based on the successful achievement of the ORR primary endpoint. PFS, the key secondary endpoint, if successfully achieved, without a detrimental effect on overall survival, could satisfy the requirement for regular approval without the requirement for a post approval confirmatory trial (in contrast to most accelerated approval trials). About TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. Following its proposed merger with Kineta, Inc., if completed, the Company expects to advance Kineta's novel VISTA inhibiting antibody into a randomized Phase 2 trial in NPM1 mutated r/r AML in combination with a menin inhibitor. In addition to its innate immune agonist product candidate, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. For more information, please visit and connect with TuHURA on Facebook, X, and LinkedIn. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding, TuHURA's IFx-Hu2.0 product candidate and anticipated Phase 3 trial, its tumor microenvironment modulators development program, its potential acquisition by merger of Kineta Inc. and the statements about Kineta's VISTA-101 development program, and any developments or results in connection with the foregoing and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities. Investor Contact: Monique KosseGilmartin GroupMonique@ View original content to download multimedia: SOURCE TuHURA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
